Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 23, 20 December 2023
Open
Access | Article
Advances of CRISPR/Cas9 in cancer research and treatment
* Author to whom correspondence should be addressed.
Abstract
Cancer is a disease that is very difficult to cure and a lot of people in the world die because of cancer. In the past, the treatments of cancer could only depend on radiotherapy, chemotherapy and surgery of removing tumors. But these ways have some weaknesses such as harming the health of the body and relapse of cancer. Whereas recently, completely curing cancer has become possible through the advances of gene-editing technologies. Due to its great effectiveness, simplicity of usage, and other advantages, the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein-9 (CRISPR/Cas9) system is a widely used gene editing technique today. But there are still many challenges that are applied to the body. For example, the CRISPR/Cas9 system has an off-target effect and there are no suitable carriers to deliver it to the area of the body. The resolution of these problems may be made possible by future developments in the CRISPR/Cas9 system. The use, restrictions, and potential uses of the CRISPR/Cas9 system in the treatment of cancer are examined in this research. In addition, this paper compares other treatments of cancer to summarize the advantages and disadvantages of different methods.
Keywords
cancer, tumor, CRISPR/Cas9 system, off-target effect, gene-editing technology
References
1. Gong C, Chen Z, Shao H, et al. “Application of CRISPR/Cas9 in tumor immunotherapy.” Chin J Immunol, 34(1):122-126 (2018).
2. Hsu, P. D., Lander, E. S., & Zhang, F. “Development and applications of CRISPR-Cas9 for genome engineering.” Cell, 157(6), 1262-1278 (2014).
3. Doudna, J. A., & Charpentier, E. “The new frontier of genome engineering with CRISPR-Cas9.” Science, 346(6213), 1258096 (2014).
4. ZhangY, Wang K, Guo Z, et al. “CRISPR/Cas9 gene editing technology and its application in tumor immunotherapy.” Chinese Journal of Medical Biotechnology,14(04):358-360+328 (2019).
5. Li, T., Yang, Y., Qi, H. et al. “CRISPR/Cas9 therapeutics: progress and prospects.” Sig Transduct Target Ther 8, 36 (2023).
6. Tian, X., Gu, T., Patel, S. et al. “CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology.” npj Precis. Onc. 3, 8 (2019).
7. Zhang J, Liu S, Zhang R. “CRISPR / Cas 9 technology specifically kills cancer cells —— new cancer treatment strategy.” Progress in Physiological Science, 48 (05): 340 (2017).
8. Wu J, Xiao R. “Off-target effects of the CRISPR / Cas 9 system and its mediated non-coding RNA editing in human cancers.” Chongqing Medical, 47 (18): 2480-2483 + 2486 (2018).
9. Katti, A., Diaz, B.J., Caragine, C.M. et al. “CRISPR in cancer biology and therapy.” Nat Rev Cancer 22, 259–279 (2022).
10. Kosicki, M., Tomberg, K. & Bradley, A. “Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements.” Nat. Biotechnol. 36, 765–771 (2018).
11. Liebowitz, M. L. et al. “Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing.” Nat. Genet. 53, 895–905 (2021).
12. Enache, O. M. et al. “Cas9 activates the p53 pathway and selects for p53-inactivating mutations.” Nat. Genet. 52, 662–668 (2020).
13. Breier D, Peer D, “Genome editing in cancer: Challenges and potential opportunities,” Bioactive Materials, 21, 394-402 (2023).
14. Veiga N, Diesendruck Y, Peer D, “Targeted nanomedicine: Lessons learned and future directions,” Journal of Controlled Release, 355, 446-457 (2023).
15. Rosenblum D, et al., “CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.” Sci.Adv. 6, eabc9450 (2020)
16. Dempster J M, Pacini C, Pantel S., et al. “Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets” Nat Commun 10, 5817 (2022)
17. T-Chuan Chen, et al."Modeling colorectal cancer using CRISPR-cas 9-mediated engineering of human intestinal organoids."Nat Med 21,256-262 (2015).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-219-0
- ISBN (Online)
- 978-1-83558-220-6
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/23/20231016
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited